American Diabetes Association--66th scientific sessions. 9-13 June 2006, Washington, DC, USA.
Jago
Charlotte
C
Thomson Scientific, Middlesex House, 34-42 Cleveland Street, London, W1T 4JE, UK. charlotte.jago@thomson.com
D000218:Adamantane / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D000069450:Liraglutide; D009570:Nitriles; D016491:Peripheral Vascular Diseases / Q000188:drug therapy*; D011719:Pyrazines / Q000494:pharmacology / Q000627:therapeutic use; D011759:Pyrrolidines; D000068900:Sitagliptin Phosphate; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use; D000077597:Vildagliptin
D009570:Nitriles; D011719:Pyrazines; D011759:Pyrrolidines; D014230:Triazoles; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1; D000077597:Vildagliptin; D000218:Adamantane; D000068900:Sitagliptin Phosphate